DrugRisk Announces Pradaxa Alternative Approved by FDA

The DrugRisk Resource Center is the Web’s largest source for information on drug and medical device warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pradaxa Diagram
Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible.

Dallas, TX (PRWEB) January 04, 2013

The prescription drug resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa that the FDA recently approved Eliquis as another alternative to warfarin and Pradaxa for the prevention of strokes in patients with atrial fibrillation.*

“The goal of DrugRisk is to improve patient safety through education of the latest drug warnings, recalls, studies and litigation news. This also includes letting consumers know of medication options so they can talk with their doctor about the safest alternative,” explains DrugRisk representative Ryan Mayer.

DrugRisk recently announced a warning by the U.S. FDA on December 19th, that patients with mechanical heart valves may face a greater risk of strokes, heart attacks, or blood clots from Pradaxa than with warfarin after results from clinical trials in Europe.**

The resource center also learned that the number of patients filing Pradaxa lawsuits over internal bleeding has risen 50% since September.*** The cases have now been moved to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Experts disagree about the safety of Pradaxa and the risk for bleeding. Last month the FDA updated warnings to say the drug carries the same risks as warfarin.**** However, the New York Times also reported doctors’ concerns that Pradaxa led all medications for adverse reports and currently has no antidote for internal bleeding.*****

Most common among the adverse reports were 6497 gastrointestinal side effects, 4910 gastrointestinal hemorrhages (bleeding) and 2941 central nervous system or cranial hemorrhaging problems. There were also 842 deaths attributed to the drug.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm
**fda.gov/Drugs/DrugSafety/ucm332912.htm
***jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets-By-District-November-2012.pdf
****fda.gov/Drugs/DrugSafety/ucm326580.htm
*****nytimes.com/2012/11/03/business/a-rising-anti-stroke-drug-is-tied-to-risk-of-bleeding-deaths.html


Contact